| Literature DB >> 27365459 |
Santosha Vardhana1, Anas Younes2.
Abstract
Classical Hodgkin lymphoma is curable in the majority of cases with chemotherapy and/or radiation. However, 15-20% of patients ultimately relapse and succumb to their disease. Pathologically, classical Hodgkin lymphoma is characterized by rare tumor-initiating Reed-Sternberg cells surrounded by a dense immune microenvironment. However, the role of the immune microenvironment, particularly T and B cells, in either promoting or restricting Classical Hodgkin lymphoma growth remains undefined. Recent dramatic clinical responses seen using monoclonal antibodies against PD-1, a cell surface receptor whose primary function is to restrict T cell activation, have reignited questions regarding the function of the adaptive immune system in classical Hodgkin lymphoma. This review summarizes what is known regarding T cells, B cells, and immune checkpoints in classical Hodgkin lymphoma. Copyright© Ferrata Storti Foundation.Entities:
Mesh:
Substances:
Year: 2016 PMID: 27365459 PMCID: PMC5004458 DOI: 10.3324/haematol.2015.132761
Source DB: PubMed Journal: Haematologica ISSN: 0390-6078 Impact factor: 9.941